MicroRNA-92a as a Potential Biomarker in Diagnosis of Colorectal Cancer: A Systematic Review and Meta-Analysis

Abstract

IntroductionPrevious studies demonstrated that MicroRNA-92a (miR-92a) was significantly differential expressed between colorectal cancer (CRC) patients and control cohorts, which provide timely relevant evidence for miR-92a as a novel promising biomarker in the colorectal cancer patients. This meta-analysis aimed to evaluate potential diagnostic value of plasma miR-92a.MethodsRelevant literatures were collected in PubMed, Embase, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI) and Technology of Chongqing (VIP), and Wan Fang Data. Sensitivity, specificity and diagnostic odds ratio (DOR) for miR-92a in the diagnosis of CRC were pooled using random effects models. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were used to estimate the overall test performance.ResultsThis Meta-analysis included six studies with a total of 521 CRC patients and 379 healthy controls. For miR-92a, the pooled sensitivity, specificity and DOR to predict CRC patients were 76% (95% confidence interval [CI]: 72%–79%), 64% (95% confidence interval [CI]: 59%–69%) and 8.05 (95% CI: 3.50–18.56), respectively. In addition, the AUC of miR-92a in diagnosis CRC is 0.7720.ConclusionsMicroRNA-92a might be a novel potential biomarker in the diagnosis of colorectal cancer, and more studies are needed to highlight the theoretical strengths.

Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study

“…This agreed with Faltejskova et al [33] who documented evidence against using it in diagnosing and monitoring CRC, contrary to many studies that confirmed its significant role in diagnosing CRC with adequate sensitivity and specificity [11,34,[37][38][39]. Even Huang et al ascertained its role when combined with miR-29a [34].…”

Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes

“…Previous studies have reported that serum and plasma miRNAs may serve as novel biomarkers for various diseases, including T2D (14,(17)(18)(19)(20)(21). Furthermore, miRNAs in peripheral whole blood have also shown promise as a novel class of biomarkers for the detection of several types of cancer, such as brain (22) and breast (23) cancer, as well as acute myocardial infarction (24), and other human diseases (25).…”

“…To date, changes in single miRNAs and in miRNA signatures have been reported in the serum and plasma of patients with various diseases, such as cancer (17,18) and cardiovascular diseases (19,20). Furthermore, a previous population-based cohort study identified a set of plasma miRNAs that were differentially expressed in patients with T2D and healthy controls (21), and among them, miR-15a was demonstrated to be the most strongly associated with T2D.…”

miR-494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN

“…furthermore, increasing numbers of mirnas have been observed in various types of cancer and may be involved in modulating cancer cell behavior (8)(9)(10). Several aberrantly expressed mirnas have been proven to be associated with tumorigenesis, tumor progression and metastasis in crc, and taken as prognostic indicators for crc including mir-150 (11), mir-28-5p/-3p (12), mir-200 (13) and many others (14)(15)(16).…”